You Can’t Buy Us: Biotechs Turn to Courts to Fight Off Potential Buyers

Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO underscore the cutthroat nature of biopharma dealmaking.